Examining Tumor Samples from Patients Undergoing Percutaneous Ablation of Liver Metastases

PRIMARY OBJECTIVE:

I. Establish that viable tumor (oxidative phosphorylation [OxPhos] antibody [AB], MitoTracker [MT] Red and Ki67 positive tumor cells) identified in tissue from the ablated tumor (adherent to the electrode and obtained with needle biopsy) is an independent predictor of local tumor progression (LTP) and ablation failure.

SECONDARY OBJECTIVES:

I. Calculate and correlate the volume of tumor perfusion and necrosis, using post-ablation dynamic liver computed tomography (CT), preferably including triphasic imaging, with the presence of viable tumor (OxPhos AB, MT Red, and Ki67 positive tumor cells) or coagulation necrosis of the tissue from the ablated tumor (adherent to the electrode and obtained with needle biopsy).

II. Correlate the presence of viable tumor (OxPhos AB, MT Red and Ki67 positive tumor cells) or coagulation necrosis of tissue from the ablated tumor (adherent to the electrode and obtained with needle biopsy) with peripheral blood levels of carcinoembryonic antigen (CEA). (Applies to patient with colon cancer liver metastases only)

III. Evaluate whether the presence of viable tumor (OxPhos AB, MT Red, and Ki67 positive tumor cells) identified in tissue from the ablated tumor (adherent to the electrode and obtained with needle biopsy) is a predictor of overall survival after percutaneous ablation of malignant colon cancer liver metastases (CLM). (Applies to patient with colon cancer liver metastases only)

OUTLINE:

Patients undergo biopsy before percutaneous ablation and an image-guided biopsy of the ablated liver tumor after percutaneous ablation.

After completion of study treatment, patients are followed up at 1-2 weeks, 4-8 weeks, and then every 2-4 months for 3 years.